- Candida glabrata
Taxobox
name = "Candida glabrata"
caption = "Candida glabrata" 1600x
regnum =Fungi
phylum =Ascomycota
subphylum =Saccharomycotina
classis =Saccharomycetes
ordo =Saccharomycetales
familia =Saccharomycetaceae
genus = "Candida"
species = "C. glabrata"
binomial = "Candida glabrata"
binomial_authority = (Anderson) Meyer & Yarrow
synonyms = "Torulopsis glabrata""Candida glabrata" is a
haploid yeast of the genus "Candida", previously known as "Torulopsis glabrata". This species of yeast is non-dimorphic and there has been no observed mating activity. Until recently, "C. glabrata" was thought to be a primarily non-pathogenic organism. However, with the ever increasing population of immunocompromised individuals, trends have shown "C. glabrata" to be a highly opportunistic pathogen of the urogenital tract, and of the bloodstream ("Candidemia "). It is especially prevalent inHIV positive people, and the elderly.There are two widely cited potential virulence factors that contribute to the pathogenicity of "C. glabrata". The first is a series of adhesins coded by the EPA (epithelial
adhesin ) genes. These genes, located in the subtelomeric region, can respond to environmental cues that allow them to be expressed en masse so the organism can adhere to biotic and abiotic surfaces in microbial mats. This is also the suspected mechanism by which "C. glabrata" forms microbial "biofilm s" on urinary catheters, and less commonly in-dwelling IV catheters. It also causes problems with dental devices, such as dentures.A major phenotype and potential virulence factor that "C. glabrata" possesses is low-level intrinsic resistance to the
azole drugs, which are the most commonly prescribed antifungal (antimycotic) drugs. These drugs, includingfluconazole andketoconazole , are quite useless against "C. glabrata". While some have said that the organism possesses an "innate" immunity to the drugs, it is more accurate to say that the organism possesses an evolved resistance to the drugs. It is still highly vulnerable to polyene drugs such asamphotericin B andnystatin , along with variable vulnerability toflucytosine andcaspofungin .References
* Sobel et al. Candida glabrata: Review of Epidemiology, Pathogenesis, and Clinical Disease with Comparison to C. albicans. [http://cmr.asm.org/cgi/content/full/12/1/80]
External links
* [http://www.doctorfungus.org/thefungi/Candida_glabrata.htm Dr. Fungus's "Candida inconspicua"]
* [http://cbi.labri.fr/Genolevures/elt/CAGL Genolevures: "Candida glabrata", Genome]
* [http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=genomeprj&cmd=Retrieve&dopt=Overview&list_uids=12362 "Candida glabrata" genome map]
Wikimedia Foundation. 2010.